Recombinant Human Chymotrypsin(OsrhCT)
PreclinicalSmall molecule
Recombinant Human Chymotrypsin(OsrhCT) is one of 5 small molecule programs targeting Hypoalbuminemia. It is currently in Preclinical.
1
Indications
3
Total Trials
3
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Hypoalbuminemia
#DrugCompanyPhaseTrials
1Thalomid
Bristol-Myers SquibbApproved
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Human Albumin
TTonghua Anrate Biopharmaceutical Co., Ltd.
Phase 3
Osrhsa
HHealthgen Biotechnology Corp.
Phase 3
Recombinant Human Chymotrypsin(OsrhCT)
HHealthgen Biotechnology Corp.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Efficacy1 trial
Hypoalbuminemia1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- HHealthgen Biotechnology Corp.